Literature DB >> 25417890

[Expert consensus on diagnosis and treatment of myelodysplastic syndrome (2014)].

.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25417890     DOI： 10.3760/cma.j.issn.0253-2727.2014.11.023

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  14 in total

1.  Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors.

Authors:  Tangxia Liu; Jing Wang; Chunmei Li; Lingzhi Jia
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

2.  [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].

Authors:  J Y Wang; J Ma; Y N Lin; J Wang; H Shen; F M Gui; C Han; Q H Li; Z Song; X J Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

3.  [Clinical and cytogenetic study of chromosome 1 abnormality in myelodysplastic syndrome].

Authors:  Wei Wang; Zhimei Chen; Mengxia Yu; Huanping Wang; Jiyu Lou; Huan Xu; Chao Hu; Qitian Mu; Hongyan Tong; Juying Wei; Xinping Zhou; Jie Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

4.  [Comparison of three different types of donor hematopoietic stem cell transplantation for intermediate and high-risk myelodysplastic syndrome].

Authors:  Y Lu; T Wu; Y L Zhao; X Y Cao; D Y Liu; M Xiong; J R Zhou; J P Zhang; Z J Wei; R J Sun; D P Lu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

5.  [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].

Authors:  Z F Xu; T J Qin; H L Zhang; L W Fang; Y Zhang; L J Pan; N B Hu; S Q Qu; B Li; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

6.  [Autophagy level of bone marrow mononuclear cells in patients with myelodysplastic syndromes].

Authors:  Lifang Guo; Ningbo Cui; Huaquan Wang; Rong Fu; Wen Qu; Erbao Ruan; Xiaoming Wang; Guojin Wang; Yuhong Wu; Hong Liu; Jia Song; Jing Guan; Limin Xing; Lijuan Li; Huijuan Jiang; Hui Liu; Yihao Wang; Chunyan Liu; Wei Zhang; Zonghong Shao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-12

7.  [Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].

Authors:  Y S Zhao; J Guo; F Xu; D Wu; L Y Wu; L L Song; C Xiao; X Li; C K Chang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-02-14

8.  [Effect of iron chelation therapy on EPO-Stat5 signaling pathway and Treg expression in IPSS low risk/medium risk-1 group myelodysplastic syndrome patients].

Authors:  Y Zhang; S Han; C Guo; Q X Zhang; C K Chang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14

9.  [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].

Authors:  J Liu; J S Jia; L Z Gong; S Y Lu; H H Zhu; X J Huang; H Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-09-14

10.  Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes.

Authors:  Xia Xiao; Xiaoyuan He; Qing Li; Wei Zhang; Haibo Zhu; Weihong Yang; Yuming Li; Li Geng; Hui Liu; Lijuan Li; Huaquan Wang; Rong Fu; Mingfeng Zhao; Zhong Chen; Zonghong Shao
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.